prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 | 27|28 |29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |39 |40 |41 |42 |43 |44 |45 |46 |47 |48 |49 |50 |51 |52 |53 |54 |55 |review

The primary and secondary endpoints  in the STARSHIP trial are displayed on the current slide.

 

The primary endpoint was the percentage change from baseline in LDL-C at 6 weeks. The secondary endpoints  consisted of safety and the following efficacy measures: proportions of patients reaching NCEP ATP III lipid goals and percentage change from baseline in other lipid measures and lipid ratios at 6 weeks, including total cholesterol (TC), apolipoprotein (Apo) B, non-HDL-C, TG, HDL-C, Apo A-I, and LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, and Apo B/Apo A-I ratios and CRP levels.1

 

Safety evaluations included monitoring of adverse events; laboratory evaluations, including clinical chemistry, hematology, and urinalysis; assessment of vital signs, and physical examination findings.1

 

Reference:

1. Lloret, R et al.  Comparison of rosuvastatin versus atorvastatin in Hispanic-American patients with hypercholesterolemia (from the STARSHIP trial). American Journal of Cardiology. 2006;98:768-773.